The estimated Net Worth of Ramkumar Mandalam is at least $1.38 Milion dollars as of 2 August 2024. Ramkumar Mandalam owns over 4,167 units of CryoPort Inc stock worth over $468,950 and over the last 10 years he sold CYRX stock worth over $532,416. In addition, he makes $376,408 as Independent Director at CryoPort Inc.
Ramkumar has made over 4 trades of the CryoPort Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 4,167 units of CYRX stock worth $21,002 on 2 August 2024.
The largest trade he's ever made was selling 11,092 units of CryoPort Inc stock on 24 November 2020 worth over $532,416. On average, Ramkumar trades about 907 units every 46 days since 2014. As of 2 August 2024 he still owns at least 60,199 units of CryoPort Inc stock.
You can see the complete history of Ramkumar Mandalam stock trades at the bottom of the page.
Dr. Ramkumar Mandalam, Ph.D., is the Independent Director of the Company. Dr. Mandalam became a member of our board of directors in June 2014 and serves as Chairman of the Governance and Nomination Committee and member of the Compensation Committee our board of directors. Dr. Mandalam is the President and CEO of Cellerant Therapeutics, Inc., a clinical stage biotechnology company developing novel cell-based and antibody therapies for cancer treatment and blood-related disorders. Under his leadership, Cellerant has developed a pipeline of candidates for treatment of heamatological malignancies and has rapidly expanded from an early-stage to an advanced clinical-stage company. Prior to joining Cellerant in 2005, he was the Executive Director of Product Development at Geron Corporation, a biopharmaceutical company where he managed the development and manufacturing of cell based therapies for treatment of degenerative diseases and cancer. From 1994 to 2000, he held various positions in research and development at Aastrom Biosciences, where he was responsible for programs involving ex vivo expansion of human bone marrow stem cells and dendritic cells. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, Michigan. Dr. Mandalam is the author or co-author of several publications, patent applications, and abstracts. Dr. Mandalam’s training as a scientist, extensive background in biotechnology and management expertise and makes him well-qualified to serve as a member of the board of directors.
As the Independent Director of CryoPort Inc, the total compensation of Ramkumar Mandalam at CryoPort Inc is $376,408. There are 8 executives at CryoPort Inc getting paid more, with Jerrell Shelton having the highest compensation of $3,839,460.
Ramkumar Mandalam is 55, he's been the Independent Director of CryoPort Inc since 2014. There are 7 older and 2 younger executives at CryoPort Inc. The oldest executive at CryoPort Inc is Richard Berman, 77, who is the Lead Independent Director.
Ramkumar's mailing address filed with the SEC is C/O CRYOPORT INC., 112 WESTWOOD PLACE, SUITE 350, BRENTWOOD, TN, 37027.
Over the last 12 years, insiders at CryoPort Inc have traded over $202,268,038 worth of CryoPort Inc stock and bought 80,292 units worth $196,910 . The most active insiders traders include Holdings Ii L.P.Blackstone ..., Richard J Berman a Jerrell Shelton. On average, CryoPort Inc executives and independent directors trade stock every 39 days with the average trade being worth of $414,958. The most recent stock trade was executed by Robert J Hariri on 19 August 2024, trading 1,000 units of CYRX stock currently worth $9,470.
cryoport delivers an innovative and complete outsourced frozen shipping solution for biological materials. this breakthrough combination replaces outdated dry ice shipping, virtually eliminates the risk of cell degradation and revolutionizes deep frozen logistics. we combine the technology of liquid nitrogen dry vapor shippers with the most advanced logistics management platform in the industry. when added with our logistics expertise, we provide a complete outsourced solution that advances deep-frozen shipping for the life science community. whether your business is bio-pharmaceuticals, clinical trials, research or reproductive medicine, you want to focus on your core mission. cryoport will help you transport life.
CryoPort Inc executives and other stock owners filed with the SEC include: